Group items matching

in title, tags, annotations or url

Eczema (atopic dermatitis), which affects up to 20 per cent of children, is one of the most common conditions pharmacists encounter, but don't underestimate eczema. Generalised eczema may compromise health-related quality of life (HRQoL) more than several other chronic diseases, including asthma, epilepsy and diabetes. Despite the impact on HRQoL, underuse of moisturisers and topical corticosteroids often leaves childhood eczema poorly controlled. UK researchers recently reported that several factors contribute to the underuse of moisturisers and topical corticosteroids in children with eczema. For instance, most of the 30 parents and carers interviewed felt that they had received little information about eczema. The lack of understanding may help explain why some parents and carers expressed concerns, such as the risk of skin thinning, about topical corticosteroids. Some were not convinced that moisturisers (strictly, an emollient is an ingredient of a moisturiser) reduced itch and maintained control of eczema. Some felt that moisturisers' efficacy declined over time. Parents and carers also admitted to "incomplete knowledge and skills" about managing eczema (such as whether they should apply moisturisers regularly) and reluctance to manage eczema in collaboration with their child. Parents and carers wanted advice about using treatments and explanations of moisturisers' and topical corticosteroids' mechanisms of action. The authors note that healthcare professionals could help identify and address gaps in knowledge.

Health technology pioneer Invatech Health has sold its care homes electronic medication administration record (eMAR) system Atlas to care home management specialists Person Centred Software (PCS). Following the transition of Atlas to new ownership, Bristol-based Invatech Health will concentrate solely on further growth of Titan, its cutting-edge software for pharmacy management. Invatech Health CEO Tariq Muhammad, a pharmacist who started working on care homes back in 2002, first conceived the concept of electronic medicines system for care homes in 2006. Muhammad said he was proud to see his purpose-driven business given an opportunity for further progress. "It's a bit like being at a child's graduation," he said, after the completion of the acquisition which marked the end of a 20 year journey for him with Atlas. "I set up Atlas to tackle a dire need in the care homes sector for a system which could prevent incorrect dosing, mismanagement of prescriptions and administration errors of important medication.

The Omicron variant of coronavirus is less likely to cause long Covid than previous variants, according to the first peer-reviewed study of its kind from the UK. Researchers at King's College London, using data from nearly 100,000 people who logged their Covid symptoms via an app, found the odds of developing long Covid after infection were 20 per cent to 50 per cent lower during the Omicron wave in the UK compared to Delta. The figure varied depending on the patient's age and the timing of their last vaccination. Long Covid, which includes prolonged symptoms ranging from fatigue to 'brain fog', can be debilitating and continue for weeks or months. It is increasingly being recognised as a public health problem, and researchers have been racing to find out if Omicron presents as big a risk of long Covid as previously dominant variants. The study from King's is believed to be the first academic research to show Omicron does not present as great a risk of long Covid, but that does not mean long Covid patient numbers are dropping, the team said. While the risk of long Covid was lower during Omicron, more people were infected, so the absolute number now suffering is higher. "It's good news, but please don't decommission any of your long Covid services," lead researcher Dr Claire Steves said, appealing to health-service providers.

Smoking increases the risk of developing schizophrenia and depression, a report by academics from the University of Bristol published on 20 June claims. It says smoking raises the risk of developing schizophrenia by between 53 per cent and 127 per cent and the risk of developing depression by from 54 per cent to 132 per cent. The authors of the report say more research is needed to identify why this is the case and that more evidence is needed to understand its impact on other mental health conditions such as anxiety or bipolar disorder. The evidence, presented at the Royal College of Psychiatrist's international congress, has been shared with the government which is currently developing a new Tobacco Control Plan for publication later this year. Action on Smoking and Health (ASH) said: "Rates of smoking are much higher among people with mental health conditions than those without, and among England's six million smokers there are an estimated 230k smokers with severe mental illness (e.g., schizophrenia and bi-polar disorder) and 1.6 million with depression and anxiety."

Ninety-six per cent of community pharmacists surveyed in the Royal Pharmaceutical Society (RPS) Workforce Wellbeing survey said they were at 'risk of burnout'. A higher number of respondents working in community pharmacy (20%) reported not being offered breaks compared to all other sectors (8%) and were more likely to experience verbal or physical abuse from patients and the public (69% vs an average 44%). The annual Workforce Wellbeing survey also revealed that 88 per cent of pharmacists surveyed are at high risk of burnout due to winter pressure. Therefore, RPS is calling for workforce planning for pharmacy to address skill mix and staffing levels so that workloads can be effectively managed. Top factors causing poor mental health and wellbeing revealed by the survey include inadequate staffing (70%), lack of work/life balance (53%), lack of protected learning time (48%) and lack of colleague/senior support (47%). This is the fourth survey RPS has run in partnership with the charity Pharmacist Support on the state of mental health and wellbeing in pharmacy. The findings demonstrate continued pressure on pharmacists and trainees across the workforce, especially in community pharmacy where 96% of those surveyed said they were at risk of burnout.

Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in humans, the incoming chief scientist at the World Health Organization said on Monday (Feb. 20). Countries ranging from the United States and Britain to France and Japan have suffered record losses of poultry in outbreaks of avian flu in the past year. The recent spread to mammals of H5N1 - commonly known as bird flu - needed to be monitored, but the risk to humans remained low, the WHO said earlier this month. Incoming WHO chief scientist Jeremy Farrar said he would like to see the pharmaceutical industry at least conduct some clinical trials for all influenza strains such that the world would not have to start from scratch to initiate global manufacturing should the need arise. "My concern that we're in slow motion watching something which may never happen," he added in a media briefing. "But if it were to happen, would we look back on what we're doing at the moment and say, why didn't we do more?"

The Department of Health and Social Care (DHSC) has introduced a new prescription pre-payment certificate (PPC) for Hormone Replacement Therapy (HRT) which is said to benefit around 400,000 women who suffer from negative symptoms of the menopause in England. PPC will be rolled-out from 1 April and it reduce the HRT costs to less than £20 a year. Women prescribed HRT - the main treatment for menopause symptoms - will have access to a new scheme enabling access to a year's worth of menopause prescription items for the cost of two single prescription charges (currently £18.70). As part of commitments to reduce the cost of HRT for menopausal women, the prescription PPC will be valid for 12 months. It can be used against a list of HRT prescription items, and a patient can use this against an unlimited number of HRT items, such as patches, tablets and topical preparations. There will be no limit to how many times the certificate can be used while it is valid. "The introduction of the certificate delivers one of our year one priorities for the Women's Health Strategy for England. Published last summer, the strategy sets out an ambitious new agenda for improving the health and wellbeing of women and girls and to improve how the health and care system listens to women. Menopause was announced as a priority area within the strategy," said DHSC.

The Company Chemists' Association (CCA)'s analysis on permanent closures of community pharmacies in England showed that there has been a net loss of 670 pharmacies between 2015 and 2022. The analysis highlighted that 37 per cent of permanent closures of pharmacies and GP practices have occurred in the 20 per cent most deprived parts of England. Current trends indicate that primary care 'cold spots' could soon emerge - areas where there is significantly reduced or inadequate access to a pharmacy or a GP. The CCA's analysis shows that some of the most deprived neighbourhoods concentrated in the North West, the West Midlands and Yorkshire have faced the highest losses of local pharmacies and GP practices since 2015. It demonstrates that the trend of permanent closures amongst pharmacies and GP practices is worsening. Moreover, this burden is likely to be felt unevenly with permanent closures occurring disproportionately in areas of high deprivation. Without action, deprived communities, where need is typically greater, may no longer be able to access the GP and pharmacy services they require.

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. This figure will nearly double every 20 years, reaching 78 million in 2030 and 139 million in 2050. The WHO Global Status Report for 2021 estimated the yearly global cost of dementia to be more than USD 1.3 trillion, with a projected increase to USD 2.8 trillion by 2030. To date most drugs developed to treat Alzheimer's disease have failed, largely because they target wrong biomarkers and individuals already exhibiting signs of the disease. Once symptoms appear, however, many brain cells responsible for memory and cognition are likely already damaged and beyond repair. Professor Shai Rahimipour in the Chemistry Department at Bar-Ilan University in Israel has pioneered a different approach utilizing theranostics to pinpoint and treat the earliest, pre-symptomatic signs of Alzheimer's disease. Showing promise in stopping progression of the disease before onset of irreversible brain cell damage, Rahimipour's groundbreaking approach has garnered significant attention in the scientific world.

Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion (£22.67bn), fortifying its rare diseases portfolio in the biggest buyout in the sector this year. The company will pay $116.50 in cash, a premium of nearly 20 per cent to the stock's last close, for each Horizon share. Horizon shares closed up 15 per cent on Monday at $112.36. They had climbed 23.5 per cent through Friday since the company disclosed in late November it was in preliminary talks with Amgen, Sanofi and Johnson & Johnson for potential offers. Amgen shares dipped less than 1 per cent to close at $276.78. Sanofi said Sunday it ended discussions with Horizon after concluding the transaction prices "do not meet our value criteria." J&J also said in early December that it had dropped its pursuit of the deal.

British pharmaceutical giant GSK said on Saturday (April 15) its oral antibiotic drug to treat uncomplicated urinary tract infections (uUTI) in female adults and adolescents met the main goals in late-stage trials. The drug, gepotidacin, in phase III trials, met its primary goals of being on a par or better than nitrofurantoin, the current standard of care for the treatment of uUTIs, the company said. GSK plans to submit results of the trials to the United States Food and Drug Administration for review later in the second quarter. The drug, if approved, could become the first new type of antibiotic, which is critically important for countering drug-resistant infections, to treat uUTIs in 20 years, the company said. "Gepotidacin, if approved, will offer a much-needed additional oral treatment option for patients at risk of treatment failure associated with resistance or recurrence of uUTI," Chris Corsico, senior vice president of development at GSK, said.

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre. The donation - the biggest in the university's history - will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide. The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding. He and Sam were on Thursday (April 20) joined by specially invited guests from across the region's health, education, and business communities, to launch the Institute housed in the University's Sciences Complex. Unveiling a plaque inside the building, John said: "It's an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today. "It's been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago. "I was immediately impressed at what has been achieved in that intervening half-century and I've been delighted to assist the University continue its development, particularly in the health arena. "I hope the launch of this institute will mark the next phase in the University's evolution and I'm very much looking forward to working with the team as they bring their projects to fruition."

Shadow Health Secretary Wes Streeting outlined his plans for NHS reform on Friday (21 April), where he also mentioned a desire to see pharmacies take on more workload and pharmacists' clinical skills to be better utilised. In his speech, he also expressed concern at warnings from the pharmacy sector and pharmacy closures. The Company Chemists' Association (CCA) appreciated Shadow Health Secretary's desire to enhance pharmacies' role in primary care reform but also stated that the sector is in urgently needs a funding injection. Dr. Nick Thayer, Head of Policy at the Company Chemists' Association (CCA) comment: "We are pleased to see the Shadow Health Secretary recognise the enhanced role that pharmacies should play in primary care reform. Mr Streeting wants to see care brought closer to people's homes and more front doors into the NHS. With 89.2% of the population located within a 20-minute walk of a pharmacy, pharmacies do just that. They are essential to realising his vision of a 'neighbourhood health service'. Pharmacies could free up over 42m GP appointments annually, including 10m vaccination appointments. Urgent same-day appointments for minor conditions in pharmacies will immediately benefit patients by increasing GP access. The first step is for the Government to immediately commission a fully-funded Pharmacy First service in England.

A BBC investigation has found 20 UK online pharmacies selling prescription-only medicines without adhering to the regulatory standards, such as checking for GP approval or patient's medical records. The news organisation was able to purchase over 1,600 restricted pills, including anti-anxiety drug, painkiller and sleeping medication, from these regulated online pharmacies easily by providing false information. However, the report didn't mention the names of the drugs as "they can be dangerous when taken without medical guidance." Some pharmacies were also found selling high-risk and potentially addictive medicines, including benzodiazepines and antidepressants, based on online questionnaires and did not require further checks. The General Pharmaceutical Council (GPhC), which regulate online pharmacies in the UK, states that selling and supplying medicines at a distance brings "different risks which need to be appropriately managed to protect patient safety."

Britain has declined to sign the World Health Organization's (WHO) proposed pandemic accord, citing concerns over the redistribution of vaccines, as reported by The Telegraph on Tuesday. The accord aims to ensure fair distribution of resources during global health crises, including reserving 20 per cent of tests, treatments, and vaccines for distribution in poorer nations. According to media reports the Department of Health and Social Care stated that they would only support the adoption of the accord if it aligns with the national interest and respects sovereignty. However, a DHSC spokesperson refrained from detailing the specific proposals within the accord, emphasising that no agreements had been reached yet. The WHO has not yet responded to requests for comment on this matter.

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the Prime Minister's commitment to create a smokefree generation. The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds for the NHS. The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets. Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under the age of 18.

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx. The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said. Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5). Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy." Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

In our quest for perfect skin, the landscape of dermatology and skin care has evolved dramatically, offering breakthrough treatments and solutions. The pursuit of a blemish-free, radiant complexion is no longer a distant dream, thanks to advancements in medical aesthetics and skincare technology. From non-invasive procedures to tailor-made skincare regimens, individuals now have access to a plethora of options designed to target specific skin concerns. This article explores the cutting-edge treatments that promise to diminish imperfections and reveal flawless skin, transforming not just how we look but also how we feel about ourselves. Botox Injections Botox, or Botulinum toxin, has gained immense popularity for its ability to smooth out wrinkles and fine lines. It works by temporarily paralyzing the facial muscles responsible for creating these imperfections. The procedure involves injecting small amounts of the neurotoxin into targeted areas, such as the forehead, crow's feet, and frown lines between the brows. The effects of Botox typically last for three to four months, making it a popular choice for those seeking quick and noticeable results. The people at sdbotox.com note that it is also a popular preventative treatment for those looking to delay the formation of wrinkles. With consistent use, Botox can actually prevent fine lines and wrinkles from appearing in the first place, making it an attractive option for individuals in their late 20s and early 30s.

Well Pharmacy's parent company, Bestway Group, announced on Wednesday (20 March) that it recorded a five per cent growth in revenues to £4.74 billion for the year ending June 2023, alongside a pre-tax profit of £420.9 million. During the year, the company also completed acquisition of Lexon UK Holdings, a leading pharmaceutical wholesaler serving over 3,000 retail pharmacy customers across the UK and Eire. Furthermore, the Group completed the construction of two cement plants in Pakistan, bringing its total cement manufacturing capacity to 15.3 million tonnes per annum. Sir Anwar Pervez OBE, founder and chairman of Bestway Group, expressed optimism about the new business year and said: "The Group has continued on its growth trajectory in 2023 and we are confident that our businesses will continue to gain share within their respective markets during 2024."